KING OF PRUSSIA, Pa.--(BUSINESS WIRE)--Merganser Biotech Inc. today announced the issuance of U.S. patent number 9,315,545 that includes a composition of matter claim for M012, Merganser’s clinical stage hepcidin mimetic peptide. M012 is currently under evaluation in a Phase 1 clinical program as a potentially transformative therapy for a number of rare hematological and iron overload diseases including beta thalassemia, low risk myelodysplasia (MDS), polycythemia vera and sickle cell disease. This patent is expected to provide exclusivity until at least 2035 and builds on the patent estate for hepcidin mimetic peptides that has been licensed by Merganser from the University of California.
“We are delighted to have been granted patent coverage on M012,” said Brian MacDonald, CEO of Merganser Biotech. “Hepcidin mimetic peptides such as M012 represent a potential new therapeutic approach to control ineffective or dysregulated erythropoiesis in a wide range of hematological diseases. The long period of exclusivity created by this patent supports continued clinical development and commercialization of this promising technology.”
Read more: http://www.businesswire.com/news/home/20160509006012/en/Merganser-Biotech-Announces-Issuance-U.S.-Patent-9315545